- E-mailJan.Hatlebakk@uib.no
- Visitor AddressHaukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst5009 Bergen
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2023). Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome. Neurogastroenterology and Motility.
- (2022). The outcome of primary per oral endoscopic myotomy (POEM) for treatment of achalasia: Norwegian single-center experience with long-term follow-up. Scandinavian Journal of Surgery.
- (2022). The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scandinavian Journal of Gastroenterology. 1036-1045.
- (2022). The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study. Microorganisms. 1-13.
- (2022). Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation. Neurogastroenterology and Motility. 1-7.
- (2022). Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 1-27.
- (2021). Ultrasound imaging for assessing functions of the GI tract. Physiological Measurement. 16 pages.
- (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2219-2237.
- (2021). Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
- (2021). Gastroparesis symptoms associated with intestinal hypomotility: An explorative study using wireless motility capsule. Clinical and Experimental Gastroenterology. 133-144.
- (2020). The effect of supplementation with low doses of a cod protein hydrolysate on satiety hormones and inflammatory biomarkers in adults with metabolic syndrome: A randomized, double-blind study. Nutrients. 1-13.
- (2020). Supplementation with low doses of a cod protein hydrolysate on glucose regulation and lipid metabolism in adults with metabolic syndrome: A randomized, double-blind study. Nutrients. 1-15.
- (2020). Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome. Medicine. 1-8.
- (2020). Density of Musashi‑1‑positive stem cells in the stomach of patients with irritable bowel syndrome. Molecular Medicine Reports. 3135-3140.
- (2020). Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility.
- (2019). Supplementation with cod protein hydrolysate in older adults: A dose range cross-over study. Journal of Nutritional Science (JNS). 1-8.
- (2019). Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Molecular Medicine Reports. 787-794.
- (2019). Nasal and salivary pepsin as a biomarker for gastro-esophageal reflux in chronic rhinosinusitis. Rhinology Online. 25-31.
- (2019). Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients.
- (2019). How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery). Gut. 1928-1941.
- (2019). Gastric emptying of low- and high-caloric liquid meals measured using ultrasonography in healthy volunteers. Ultrasound International Open. E27-E33.
- (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study . Gut. 1-9.
- (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut.
- (2019). Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients. 1-13.
- (2019). Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 1-15.
- (2019). Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scandinavian Journal of Gastroenterology. 690-699.
- (2019). Acute effect of a cod protein hydrolysate on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects: a double-blind crossover trial. Food & Nutrition Research (FNR). 1-9.
- (2018). The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLOS ONE. 1-17.
- (2018). The effect of a controlled gluten challenge in a group of patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Neurogastroenterology and Motility. 1-10.
- (2018). Navigated retrograde endoscopic myotomy (REM) for the treatment of therapy-resistant achalasia. Neurogastroenterology and Motility. 6 pages.
- (2018). Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: A double-blind cross-over trial. Journal of Nutritional Science (JNS). 9 pages.
- (2017). The dynamics of the oesophageal squamous epithelium `normalisation´ process in patients with gastro-oesophageal reflux disease treated with long-term acid suppression or anti-reflux surgery. Alimentary Pharmacology and Therapeutics. 1339-1349.
- (2017). Interaction between diet and gastrointestinal endocrine cells. Biomedical Reports. 651-656.
- (2017). Gastro-oesophageal reflux in patients with chronic rhino-sinusitis investigated with multichannel impedance - pH monitoring. Rhinology. 27-33.
- (2017). Gastric accommodation in healthy subjects studied by ultrasound, manometry, and impedancemetry. Neurogastroenterology and Motility. 1-9.
- (2017). Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1331-1339.
- (2017). Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 1-9.
- (2017). Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years. Scandinavian Journal of Gastroenterology. 11-17.
- (2017). Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 691-697.
- (2017). Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports. 2106-2112.
- (2016). Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy. Clinical Gastroenterology and Hepatology. 678-685.e3.
- (2016). Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats. Molecular Medicine Reports. 4967-4974.
- (2016). Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats. Molecular Medicine Reports. 12-20.
- (2015). Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World Journal of Gastroenterology (WJG). 9577-9587.
- (2015). Peroral endoscopic pyloromyotomy for primary pyloric stenosis. Endoscopy.
- (2015). Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology and Therapeutics. 1162-1174.
- (2015). Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: A post hoc analysis of the LOTUS trial. Current Medical Research and Opinion. 65-73.
- (2015). Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 12-19.
- (2014). Stomach antral endocrine cells in patients with irritable bowel syndrome. International Journal of Molecular Medicine. 967-974.
- (2014). Endocrine cells in the ileum of patients with irritable bowel syndrome. World Journal of Gastroenterology (WJG). 2383-2391.
- (2014). Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterology Research and Practice. 8 pages.
- (2014). Do patients with functional chest pain have neuroplastic reorganization of the pain matrix? A diffusion tensor imaging study. Scandinavian Journal of Pain. 85-90.
- (2014). Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF-κB Inhibitors in Rats. Scientific World Journal. 8 pages.
- (2014). Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regulatory Peptides. 60-65.
- (2013). Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 564-572.
- (2013). Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scandinavian Journal of Gastroenterology. 1010-1017.
- (2013). Low‑grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Molecular Medicine Reports. 1081-1085.
- (2013). Evaluation of the usefulness of colonoscopy with mucosal biopsies in the follow-up of TNBS-induced colitis in rats. Molecular Medicine Reports. 446-450.
- (2013). Colonoscopy with mucosal biopsies in young rats: A model for experimental gastroenterology. Molecular Medicine Reports. 1757-1760.
- (2013). Chronic fatigue in patients with unexplained self-reported food hypersensitivity and irritable bowel syndrome: validation of a Norwegian translation of the Fatigue Impact Scale. Clinical and Experimental Gastroenterology. 101-107.
- (2013). Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report. BMC Research Notes. 11 pages.
- (2013). Central response to painful electrical esophageal stimulation in well-defined patients suffering from functional chest pain. Neurogastroenterology and Motility. E718-E727.
- (2013). Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications. European Journal of Gastroenterology and Hepathology. 531-538.
- (2012). The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). International Journal of Molecular Medicine. 723-731.
- (2012). Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies. International Journal of Clinical Practice. 897-905.
- (2012). Randomised clinical trial: a comparison between a GerdQ‐based algorithm and an endoscopy‐based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics.
- (2012). Randomised clinical trial: a comparison between a GerdQ-based algorithm and an endoscopy-based approach for the diagnosis and initial treatment of GERD. Alimentary Pharmacology and Therapeutics. 1290-1300.
- (2012). Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome. Digestive Diseases and Sciences. 873-878.
- (2012). Irritable bowel syndrome: the role of gut neuroendocrine peptides. Frontiers in Bioscience-Elite (FBE). 2783-2800.
- (2012). High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World Journal of Gastroenterology (WJG). 6070-6075.
- (2012). Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Alimentary Pharmacology and Therapeutics. 959-971.
- (2012). Chromogranin A cell density as a diagnostic marker for lymphocytic colitis. Digestive Diseases and Sciences. 3154-3159.
- (2011). Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled anlysis of five European cluster-randomized studies. Therapeutic Advances in Gastroenterology. 11-26.
- (2011). Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD The LOTUS Randomized Clinical Trial. Journal of the American Medical Association (JAMA). 1969-1977.
- (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut. 1182-1188.
- (2010). Sensation evoked by esophageal distension in functional chest pain patients depends on mechanical stress rather than on ischemia. Neurogastroenterology and Motility. 1170-+.
- (2010). Mechanosensation and Mucosal Blood Perfusion in the Esophagus of Healthy Volunteers Studied with a Multimodal Device Incorporating Laser Doppler Flowmetry and Endosonography. Digestive Diseases and Sciences. 312-320.
- (2010). Long-Term Outcome of Microscopic Esophagitis in Chronic GERD Patients Treated With Esomeprazole or Laparoscopic Antireflux Surgery in the LOTUS Trial. American Journal of Gastroenterology. 1015-1023.
- (2010). Endoscopy in gastro-oesophageal reflux disease. Baillière's Best Practice & Research : Clinical Gastroenterology. 775-786.
- (2009). Mucosal blood flow measurements using laser Doppler perfusion monitoring. World Journal of Gastroenterology (WJG). 198-203.
- (2009). Management of gastro-oesophageal reflux disease in primary care: a European observational study. Current Medical Research and Opinion. 2777-2784.
- (2009). Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health and Quality of Life Outcomes. 7 pages.
- (2009). Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health and Quality of Life Outcomes. 8 pages.
- (2009). Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clinical Gastroenterology and Hepatology. 1292-1298.
- (2008). Standardization of surgical technique in antireflux surgery: The LOTUS trial experience. World Journal of Surgery. 995-998.
- (2008). Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. 1207-1213.
- (2008). Center for drug evaluation and research. Clinical white paper for the CDER-PHRMA-AASLD conference on drug-induced liver disease: A national and global problem. American Journal of Gastroenterology. 20-26.
- (2007). Medical therapy of gastroesophageal reflux disease. Current Opinion in Gastroenterology. 434-439.
- (2007). Advanced imaging and visualization in gastrointestinal disorders. World Journal of Gastroenterology (WJG). 1408-1421.
- (2006). Novel developments in non-erosive and erosive gastroesophageal reflux disease. Current Opinion in Gastroenterology.
- (2006). Dysphagia in the course of gastro-oesophageal reflux before surgery. Acta Endoscopica. 545-554.
- (2006). A multimodal laser Doppler and endosonographic distension device for studying mechanosensation and mucosal blood flow in the oesophagus. Neurogastroenterology and Motility. 243-248.
- (2005). Apotekpersonalets egenvurdering av kompetanse og faglig selvtillit. Norsk Farmaceutisk Tidsskrift. 17-20.
- (2004). Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: Multicenter study of the gatekeeper reflux repair system. Endoscopy. 682-689.
- (2004). Diagnostic approach to suspected irritable bowel syndrome. Baillière's Best Practice & Research : Clinical Gastroenterology. 735-746.
- (2004). Behandling av gastroøsofageal refluks hos gravide. Tidsskrift for Den norske legeforening. 797-798.
- (2000). Proton pump inhibitors: better before breakfast than without breakfast. Alimentary Pharmacology and Therapeutics. 1267-1272.
- (2000). Oesophagusstriktur som komplikasjon til gastrøsofageal refluks hos barn. Tidsskrift for Den norske legeforening. 187-189.
- (2000). Long-term management of gastro-oesophageal reflux disease with omeprazole or open anti-reflux surgery: results of a prospective, randomized clinical trial. European Journal of Gastroenterology and Hepathology. 879-887.
- (2000). Gastric acidity and acid breakthrough on omeprazole 20mg b.i.d. or lansoprazole 30mg b.i.d. Alimentary Pharmacology and Therapeutics. 709-714.
- (1999). Therapy for heartburn in primary care patients - an 8 weeks randomized double-blind study of omeprazole versus cisapride and placebo. BMJ. British Medical Journal. 550-553.
- (1999). The effect of eradication of H.pylori on gastro-oesophageal reflux. Diseases of the esophagus. 915-920.
- (1999). Spiromycin is comparable to oxytetracycline in eradicating H. pylori when given with ranititine bismuth citrate and metronidazole. Alimentary Pharmacology and Therapeutics. 651-659.
- (1999). On demand therapy of reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Alimentary Pharmacology and Therapeutics. 1035-1040.
- (1999). Medical therapy: Management of the refractory patient. Gastroenterology Clinics of North America. 847-860.
- (1999). Lack of effect of acid suppression on gastric atrophy. Nordic GERD Study Group. Gastroenterology. 319-326.
- (1999). Intragastric distribution and volume estimation of a liquid meal in patients with gastro-oesophageal reflux disease assessed by three-dimensional ultrasonography. Gut. 180.
- (1999). Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. American Journal of Gastroenterology. 1464-1467.
- (1999). Effect of Omeprazole (PPI) on Ratio of Acid to Nonacid Gastroesophageal Reflux. Studies Using Simultaneous Intraesophageal Impedance and pH Measurement. Gastroenterology. G910.
- (1999). Effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Alimentary Pharmacology and Therapeutics. 915-920.
- (1998). Outcome of open anti-reflux surgery as assessed in a Nordic multicentre, prospective clinical trial. The European Journal of Surgery. 751-757.
- (1998). Obesity and gastroesophageal reflux. Motility. 4-6.
- (1998). Gastroesophageal reflux in morbid obese patients treated with gastric banding or vertical banded gastroplasty. Annals of Surgery. 51-58.
- (1998). Gastro-oesophageal reflux disease in primary care - an international study of different treatment strategies with omeprazole. European Journal of Gastroenterology and Hepathology. 119-124.
- (1998). Endoscopic ultrasound - a new look at achalasia? European Journal of Gastroenterology and Hepathology. 543-545.
- (1998). Dysphagia in the elderly: Diagnostic approach and clinical management. Clinical Geriatrics. 16-26.
- (1998). Dilatation therapy for dysphagia in patients with upper esophageal sphincter dysfunction - manometric and symptomatic response. Diseases of the esophagus. 254-259.
- (1998). Barretts øsofagus. Et økende problem. Tidsskrift for Den norske legeforening. 4100-4103.
- (1997). The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scandinavian Journal of Gastroenterology. 1100-1106.
- (1997). Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Alimentary Pharmacology and Therapeutics. 1093-1099.
- (1997). Lansoprazole 15 and 30 mg daily in maintenance therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics. 365-372.
- (1997). Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut. 740-747.
- (1997). Endoscopic grading of reflux oesophagitis: what observations correlate with gastro-oesophagal reflux? Scandinavian Journal of Gastroenterology. 760-765.
- (1996). Pharmacokinetic optimisation in the treatment of gastrooesophageal reflux disease. Clinical Pharmacokinetics. 386-406.
- (1996). Lansoprazole 15 and 30 mg daily in maintenanxe therapy of reflux oesophagitis. Alimentary Pharmacology and Therapeutics.
- (1996). Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scandinavian Journal of Gastroenterology. 954-958.
- (1996). Bismuth-based combination therapy for Heliobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). American Journal of Gastroenterology. 935-941.
- (1995). Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Alimentary Pharmacology and Therapeutics. 197-200.
- (1994). Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
- (1994). Ti dagers trippelkur for Helicobacter pylori-infeksjon og magesår: Status fire uker og ett år etter. Tidsskrift for Den norske legeforening. 2477-2479.
- (1994). Prokinetica ved reflukssykdom. Virkningsmekanismer og klinisk effekt. Tidsskrift for Den norske legeforening. 689-692.
- (1994). Konferanserapport Digestive diseases WEEK 1994. Therapia medica.
- (1993). Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scandinavian Journal of Gastroenterology. 224-228.
Academic lecture
- (2021). Kort- og langtidseffekten av lav FODMAP-dietten på symptomer og kortkjedede fettsyrer hos pasienter med irritabel tarmsyndrom.
- (2020). Short and extended effects of a low FODMAP diet on symptoms and short-chained fatty acids in patients with irritable bowel syndrome.
- (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.
- (2020). Kvalitetsevaluering av tverrfaglig IBS-poliklinikk .
- (2020). Kort- og langtidseffekten av lavFODMAP-diett på symptomer og mikrobiota hos pasienter med IBS .
- (2020). Chromoendoscopy with Iodine-Potassium iodine solution in eosinophilic esophagitis.
- (2019). Mage-tarmskolen – tverrfaglig internetbehandling ved Irritabel tarmsyndrom .
- (2019). Effect of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome.
- (2019). CHROMOENDOSCOPY WITH IODINE-POTASSIUM IODINE SOLUTION IN EOSINOPHILIC ESOPHAGITIS.
- (2017). Navigated Retrograde Endoscopic Myotomy (REM) for the Treatment of Therapy-Resistant Achalasia.
- (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
- (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial.
- (2015). Per Oral Endoskopisk Pyloromyotomi (POP) for primær pylorusstensose.
- (2014). Per Oral Endoskpoisk Myotmi (POEM) for behandling av akalasi.
- (2013). Endoskopisk behandling av tidlig spiserøreskreft.
- (2000). Intragastric maldistribution in patients with reflux oesophagitis studied by an accurate 3D ultrasound system.
- (2000). Evaluation of a symptomatic score for the diagnosis of GERD.
- (1998). On demand therapy of reflux oesophagitis: a study of symptoms, patient satisfaction and quality of life.
- (1996). Utredning av ikke-kardiale brystsmerter.
- (1996). Transient LES-relaksasjon ved reflukssykdom.
- (1994). Lansoprazole and amoxicillin oral suspension in the treatment of peptic ulcer disease.
- (1994). Follow-up on 227 Patients with Peptic Ulcer Disease One Year after Eradication of Helicobacter Pylori.
- (1993). Lansoprazole in the treatment of reflux oesophagitis: A survey of clinical studies.
Book review
- (2021). Minneord: Arnold Berstad (1940-2020). Tidsskrift for Den norske legeforening. 293-293.
Popular scientific article
- (2014). Per Oral Endoksopisk Myotomi (POEM)for akalasi. NFG-nytt. 4 pages.
- (2013). Correct use of proton pump inhibitors for gastro-oesophageal reflux disease. Tidsskrift for Den norske legeforening. 43-46.
Feature article
- (2000). Heartburn treatment in primary care. Letter to the editor. BMJ. British Medical Journal. 1406.
Academic chapter/article/Conference paper
- (2013). Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones. 13 pages.
- (2005). Ultrasound in Patients with Gastroesophageal Reflux Disease. 30 pages.
- (1993). Verdi av pH-måling og manometri status 1993. 9 pages.
Abstract
- (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. United European Gastroenterology journal. 635-636.
- (2020). Long-term effects of faecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. United European Gastroenterology journal. 46-46.
- (2020). Changes in fecal short-chain fatty acids (SCFA) following fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility.
- (2018). Interdisciplinary self- help intervention for IBS - eHealth and patient education. Neurogastroenterology and Motility. 182-183.
- (2018). Effects of faecal microbiota transplantation on gut microenvironment and symptoms in patients with irritable bowel syndrome. Neurogastroenterology and Motility. 178-179.
- (2017). The effect of a controlled gluten challenge in patients with suspected non-coeliac gluten sensitivity: A randomized, double-blind placebo-controlled challenge. Clinical Nutrition. 32-33.
- (2017). Gluten causes symptom relapse in a small group of patients with suspected non-celiac gluten sensitivity: A randomized, double-blind placebo controlled challenge. Neurogastroenterology and Motility. 68-69.
- (2017). Effect of faecal microbiota transplantation on the symptoms and gut microbiota in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility. 73-74.
- (2017). Effect of faecal microbiota transplantation on gut bacterial fermentation products in patients with irritable bowel syndrome. United European Gastroenterology journal. A563-A564.
- (2016). The Gastric Accomodation Reflex Studied by Ultrasound, Manometry and Impedancemetry in a Pilot Study. United European Gastroenterology journal. 675-675.
- (2016). Low FODMAP diet alters symptoms, microbiota, short-chain fatty acids and cytokine profiles in patients with IBS: A randomized controlled trial. United European Gastroenterology journal. A101-A101.
- (2016). Kinetics of microbial community composition in patients with diarrhea-predominant irritable bowel syndrome following faecal microbiota transplantation. United European Gastroenterology journal. LB11-LB11.
- (2016). Effect of fecal microbiota transplantation on the symptoms and duodenal enteroendocrine cells in patients with irritable bowel syndrome. United European Gastroenterology journal. 677-677.
- (2012). Duodenal mucosal lymphocyte subgroups in patients with persisting abdominal symptoms after Giardia lamblia infection. Neurogastroenterology and Motility. 172-172.
- (2011). Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. International Journal of Molecular Medicine. S10-S10.
- (2010). Patients with functional chest pain have an increased oesophageal wall tone during bag distension. Scandinavian Journal of Gastroenterology. 45-45.
- (2009). Mechanosensation and mucosal blood perfusion during bag distension in the esophagus in patients with functional chest pain. Scandinavian Journal of Gastroenterology. 38-38.
- (2009). Changes in prescriptions dispensed for proton pump inhibitors (PPIs) following new restrictions on reimbursement - a nationwide Norwegian prescription database study. Scandinavian Journal of Gastroenterology. 39-39.
- (2009). CHANGES IN PRESCRIPTIONS DISPENSED ON PROTON PUMP INHIBITORS (PPIS) FOLLOWING NEW RESTRICTIONS FOR REIMBURSEMENT - A NATIONWIDE NORWEGIAN PRESCRIPTION DATABASE STUDY. Value in Health. A58-A58.
- (2007). Postprandial symptoms in healthy subjects improve in the left lateral supine position. Scandinavian Journal of Gastroenterology. 24-24.
Academic literature review
- (2021). Current status of fecal microbiota transplantation for irritable bowel syndrome. Neurogastroenterology and Motility. 1-8.
- (2019). Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Nutrients. 1-7.
- (2019). Pathophysiology of idiopathic gastroparesis and implications for therapy. Scandinavian Journal of Gastroenterology. 8-17.
- (2017). Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel Disease. World Journal of Gastroenterology (WJG). 5068-5085.
- (2016). The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology. 139-148.
- (2016). Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scandinavian Journal of Pain. 111-122.
- (2015). The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome. Nutrition Journal.
- (2014). Is irritable bowel syndrome an organic disorder? World Journal of Gastroenterology (WJG). 384-400.
- (2014). Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Review of Gastroenterology & Hepatology. 435-443.
- (2014). Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review). International Journal of Molecular Medicine. 363-371.
- (2014). Chronic constipation and treatment options (Review). Molecular Medicine Reports. 3-8.
- (2013). The role of peptide YY in gastrointestinal diseases and disorders (Review). International Journal of Molecular Medicine. 275-282.
- (2013). Gastroesophageal Reflux and Rhinosinusitis. Current Allergy and Asthma Reports. 218-223.
- (2013). Clinical presentation, diagnosis, pathogenesis and treatment options for lymphocytic colitis (Review). International Journal of Molecular Medicine. 263-270.
- (2012). Irritable bowel syndrome: treatment options. Clinical Practice. 591-600.
- (2008). Clinical trial design in adult reflux disease: a methodological workshop. Alimentary Pharmacology and Therapeutics. 107-126.
Chapter
- (2017). Sykdommer i øsofagus. 326-333. In:
- (2017). Indremedisin I & II. Forlaget Vett & Viten AS.
More information in national current research information system (CRIStin)